Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579103 | 1.00 | MTNR1A (0.57) | MTNR1AMTNR1BMEN1KMT2AATM | |
| SCHEMBL11230310 | 0.92 | MTNR1A (0.53) | MTNR1AMTNR1BMEN1KMT2AATM | |
| SCHEMBL10829122 | 0.80 | MTNR1B (0.46) | MTNR1AMTNR1BMEN1KMT2AATM | |
| SCHEMBL9818797 | 0.80 | PPARG (0.52) | MTNR1AMTNR1BMEN1KMT2AATM | |
| SCHEMBL10875225 | 0.77 | HTR1D (0.47) | — | |
| SCHEMBL30200767 | 0.77 | MTNR1A (0.42) | MTNR1AMTNR1BMEN1KMT2AATM | |
| SCHEMBL2402576 | 0.76 | MTNR1A (0.44) | MTNR1AMTNR1B | |
| SCHEMBL3577544 | 0.76 | TRPV4 (0.46) | MEN1KMT2APPARGPPARAHPGD | |
| SCHEMBL20514905 | 0.76 | MTNR1A (0.50) | MTNR1AMTNR1B | |
| SCHEMBL11212797 | 0.76 | MTNR1A (0.53) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | MTNR1A 1758/4885MTNR1B 1759/4885MEN1 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.